RecruitingPhase IIFemale onlyEN original
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
NCT05933395Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety po menopauzie, w wieku 18 lat lub więcej, z rakiem piersi ER+ w stadium zaawansowanym lub nawrotowym.
- •Pacjentka musi być po menopauzie zgodnie z wytycznymi.
- •Pacjentka musiała być leczona lekiem z grupy CDK4/6i (palbociclib, rybociclib lub abemacylib) samodzielnie lub z innym lekiem hormonalnym w zaawansowanej chorobie.
- •Leczenie mogło obejmować do 3 linii terapii po zastosowaniu CDK4/6i.
- •Wymagane potwierdzenie raka piersi ER+ badaniem histologicznym (np. biopsja).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 20, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Dartmouth Hitchcock Medical Center
Lebanon, United States
Trial contact
Research Nurse
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.